Active
Cardiotoxicity in children and adolescents with acute leukemia: Recommendations from the Leukemia Committee of the French Society of Childhood Cancer (SFCE)
Overview
Cardiotoxicity is a significant long-term concern in children treated for leukemia, particularly with anthracyclines. Current SFCE recommendations highligh the need for early prevention, regular cardiovascular monitoring, and prompt management of cardiac complications , it support the use of dexrazoxane in patients receiving high cumulative anthracycline doses and advocate for multidisciplinary follow-up using sensitive imaging techniques to detect subclinical cardiac dysfunction at an early stage.
